North Brunswick, New Jersey -- Biotechnology company BioAegis Therapeutics has received $1.5 million in new equity venture capital investment, according to an SEC regulatory filing.
BioAegis says that its products promise to restore depleted levels of plasma gelsolin, which is an integral natural human protein.
The gelsolin substance was first discovered by company founder Thomas Stossel.
The technology aims to provide an immunotherapeutic approach to fighting pathogens in inflammation and infection.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
One investor made the investment.
The company is still seeking $3.5 million in additional equity investment, according to the filing.